Click here to Register    
Clinical Dialogue
& eCase Challenge
spacer spacer MS-Journal Club spacer Ask The Experts
  "Understanding the Role of the Immune System in Multiple Sclerosis and Other Autoimmune Diseases"
CME InfoHelp
Jointly Provided by: The University of Texas Southwestern Medical Center and Medical Logix, LLC
Release Date: December 21, 2017
Expiration Date: December 21, 2018
Estimated time to complete activity: 30 minutes for each of the three programs. Each part of this activity has been approved for a maximum of 0.50 TM.
Acknowledgement of Commercial Support: Supported by an independent educational grant from EMD Serono.
Learning Objectives
After participating in this activity, the participant will demonstrate the ability to:
  • Explain the autoimmune basis of MS.
  • Discuss shared and unique pathophysiologic pathways between MS and other autoimmune diseases.
  • Outline mechanisms of action of current and investigational MS therapies.
  • List the major considerations associated with long-term immunosuppression in treating MS.
  • Outline strategies to address the consequences of long-term immunosuppression in treating MS.
As an accredited provider, UT Southwestern Medical Center requires that the content of our activities are:
  • Independent, objective, scientifically rigorous, balanced and free of bias.
  • Based on scientific studies utilized or referenced from sources acceptable to the scientific and medical community.
  • Acceptable to the medical community as it relates to patient recommendations and do not recommend any unscientific modalities or those not supported by evidenced based sources.
Statement of Need
An understanding of the mechanisms involved in MS is pivotal to appreciating the autoimmune basis of this disease, its pathophysiologic processes, and commonalities with other autoimmune disorders. Such knowledge is also fundamental to comprehending the variety of mechanisms of action employed by current therapies for MS. As is the case with several other autoimmune diseases, MS is a chronic condition for which there is no cure, requiring life-long therapy with immunosuppressive medications. Continuous treatment with such agents raises concerns regarding risks that patients may face during long-term immunosuppression, such as lymphopenia, infections and malignancies. Unfortunately, MS-treating clinicians are currently ill equipped to address these potentially serious complications. Productive communication with other clinicians involved in managing individuals receiving long-term immunosuppressive therapies, such as rheumatologists and infectious disease physicians, could help MS-treating physicians become better informed regarding pivotal considerations and enhance the care of their patients in daily practice.
Intended Audience
This activity is intended for healthcare professionals, specifically, neurologists, internists, family practice physicians, nurse practitioners, physician assistants, nurses and other providers involved in the care of patients with multiple sclerosis.
Contributors and Planners
Julius Birnbaum, MD, MHS
Assistant Professor of Medicine
Department of Neurology and
Division of Rheumatology
Associate Director
Johns Hopkins Jerome L. Greene Sjögren’s Center
Johns Hopkins University School of Medicine
Baltimore, MD
Bruce Cree, MD, PhD, MAS
Associate Professor of Clinical Neurology
Multiple Sclerosis Center Clinical Research Director
University of California, San Francisco
San Francisco, CA
Benjamin M. Greenberg, MD, MHS
Vice Chair of Translational Research and Ambulatory Care
Department of Neurology and Neurotherapeutics
Director, Transverse Myelitis, Neuromyelitis Optica Programs
Co-Director, Pediatric CONQUER Program
UT Southwestern Medical Center
Childrens Health
Dallas, Texas
Shaida Khan, DO
Assistant Instructor
Department of Neurology and Neurotherapeutics
UT Southwestern Medical Center
Dallas, Texas
John Babich, MD
Laura Banks, MD
Donald A. Barone, DO
David W. Brandes, MD, MS, FAAN
Nicholas Capozzoli, MD
Albert Cook, MD
Joanna Cooper, MD
Russell S. Dickerson, MD
Shervin Eshraghi, MD, MS
Simon Fishman, MD
Robert Fox, MD, PhD
David Greenberg, MD
Aunali S. Khaku, MD
John M. Kilian, MD
Aliya Lalji, MD
Collin McClelland, MD
Shannon Overs, MD, MCR
Perry K. Richardson, MD
Clifford Reed, MD
Rodrigo Rodriguez, Jr., MD
Ted Rothstein, MD
Shiv Saidha, MBBCh, MD, MRCPI
Galina Simkin, MD
Benjamin J. Smith, PA-C, DFAAPA
Joseph Sobelman, MD
Bruce Cree, MD, PhD, MAS
Consultant: Abbvie, Biogen, EMD Serono, Novartis, Shire
Benjamin M. Greenberg, MD, MHS
Consultant: EMD Serono, Novartis
Research Activities: Chugai, Medimmune, Acorda, Genentech, NIH, PCORI, NMSS
Shaida Khan, DO
No relevant financial relationships to disclose
Laura Banks, MD
Speaker’s Bureau: Teva
Donald A. Barone, DO
Research Activities: Bayer, Sun Pharma, Acorda
Speaker’s Bureau: Teva, Sanofi-Genzyme, EMD Serono, Biogen, Genentech
Consultant: Biogen, Bayer, EMD Serono, Genentech
David W. Brandes, MD, MS, FAAN
Research Activities: Mallinkrodt, Novartis
Speaker’s Bureau: Biogen, Sanofi-Genzyme, Novartis, Teva, Acorda, Avanir, Mallinkrodt
Shervin Eshraghi, MD, MS
Speaker’s Bureau: EMD Serono
Robert Fox, MD, PhD
Consultant: Celgene, Novartis
Clifford Reed, MD
Speaker’s Bureau: Teva, Genzyme, EMD Serono, Biogen, Genentech, Novartis, Acorda
Ted Rothstein, MD
Research Activities: Novartis
Speaker’s Bureau: Teva
Shiv Saidha, MBBCh, MD, MRCPI
Formal Advisor: Genzyme, EMD Serono, Biogen, Genentech, Novartis
Research Activities: Biogen, Genentech
Ownership Interest: Equity with JuneBrain a company developing imaging devices
Benjamin J. Smith, PA-C, DFAAPA
Formal Advisor: Member, ABIM Rheumatology Board
Scientific Editor, American College of Rheumatology/Association of Rheumatology Advanced
Rheumatology Course
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
The following Medical Logix, LLC planners/managers, Michael Speidel and John Gentile, and Nancy Baxter, Baxter Medical Communications, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following UT Southwestern employee, Kimberly R. Jones, MHA hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Off-Label Discussion
Bruce Cree, MD, PhD, MAS – Cladribine, Ibudilast, Laquinimod, MD1003, Ofatumumab, Opicinumab, Ozanimod, Rituximab, Siponimod
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The University of Texas Southwestern Medical Center and Medical Logix LLC. The University of Texas Southwestern Medical Center is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Texas Southwestern Medical Center designates each of these enduring materials for a maximum of 0.50 TM. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Format and Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the accreditation period, participants must read the learning objectives and faculty disclosures and review this internet-based activity. To take the post-test, please click on the post-test button below the slide window of the player. Complete the post-test and evaluation and attest to the amount of time spent in the activity. Upon receiving a score of 70% or above, print your CME certificate.
For CME questions, please contact the UTSW Office of CME at (214) 648-2166.
Technical Requirements
Processor Speed:  Dual Core with 2 GHz or above
Memory:  1024 (512MB available)
Operating Systems Supported: Win XP/windows 7 or above, MAC
Browsers Supported:  IE8 or above, Firefox 20.X or above, Safari 5.0X or above
Connection Speed:  256Kbps or better
Technical Questions:
Please click on the Help button within the online player, or email MS-Leaders at
© 2017 The University of Texas Southwestern Medical Center and Medical Logix, LLC. All rights reserved.
MS-Leaders™ is a trademark of Medical Logix, LLC.
© 2010 Medical Logix, LLC. All rights reserved